Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Change in Cash (2016 - 2025)

Conmed (CNMD) has disclosed Change in Cash for 16 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash rose 113.48% year-over-year to $1.9 million, compared with a TTM value of $16.4 million through Dec 2025, up 9935.58%, and an annual FY2025 reading of $16.4 million, up 9935.58% over the prior year.
  • Change in Cash was $1.9 million for Q4 2025 at Conmed, down from $5.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $28.3 million in Q2 2022 and bottomed at -$19.8 million in Q3 2022.
  • Average Change in Cash over 5 years is $673050.0, with a median of $1.6 million recorded in 2023.
  • Peak annual rise in Change in Cash hit 708.47% in 2021, while the deepest fall reached 2519.02% in 2021.
  • Year by year, Change in Cash stood at -$10.7 million in 2021, then soared by 58.63% to -$4.4 million in 2022, then plummeted by 40.66% to -$6.2 million in 2023, then tumbled by 125.72% to -$14.0 million in 2024, then surged by 113.48% to $1.9 million in 2025.
  • Business Quant data shows Change in Cash for CNMD at $1.9 million in Q4 2025, $5.0 million in Q3 2025, and -$1.5 million in Q2 2025.